Contact
searchSearch
HMP Global
Login

Colorectal Cancer Resource Center

Featured

Jeanne Tie, MBChB, MD, Peter MacCallum Cancer Centre
Videos
Circulating Tumor DNA-Guided vs Standard Management of Locally Advanced Rectal Cancer
01/20/2024
Jeanne Tie, MBChB, MD
Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.
Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.
Professor Jeanne Tie, MBChB,...
01/20/2024
Oncology
From Oncology
Conference Coverage
Significance of ctDNA Clearance Following Adjuvant Chemotherapy Among Patients with Radically Resected Colorectal Cancer
01/20/2024
Allison Casey
According to updated results from a substudy of the observational GALAXY study, detection of MRD via ctDNA and ctDNA dynamics in response to adjuvant chemotherapy for colorectal cancer were found to be highly prognostic of patient outcomes in...
According to updated results from a substudy of the observational GALAXY study, detection of MRD via ctDNA and ctDNA dynamics in response to adjuvant chemotherapy for colorectal cancer were found to be highly prognostic of patient outcomes in...
According to updated results...
01/20/2024
Oncology
From Oncology
Conference Coverage
Role of ctDNA to Guide Adjuvant Chemotherapy Use for Patients With Colon Cancer
01/20/2024
Allison Casey
In the phase 2/3 COBRA study no improvement in ctDNA clearance was observed after 6 months of chemotherapy among patients with ctDNA detected following resection of stage IIA colon cancer.
In the phase 2/3 COBRA study no improvement in ctDNA clearance was observed after 6 months of chemotherapy among patients with ctDNA detected following resection of stage IIA colon cancer.
In the phase 2/3 COBRA study no...
01/20/2024
Oncology
From Oncology
Kristin Savill, PhD
Videos
Evaluating Real-World Utilization of ctDNA Testing in the Management of Patients With Colorectal Cancer
06/30/2022
Kristin Savill, PhD, discusses her survey-based study that evaluated the utilization of circulating tumor DNA testing in the management of colorectal cancer among practicing community oncologists in the US.
Kristin Savill, PhD, discusses her survey-based study that evaluated the utilization of circulating tumor DNA testing in the management of colorectal cancer among practicing community oncologists in the US.
Kristin Savill, PhD, discusses...
06/30/2022
Journal of Clinical Pathways
News
Bevacizumab-bvzr Biosimilar Used Most Frequently for Metastatic Colorectal Cancer in US Oncology Practice, According to Retrospective Cohort Study
06/09/2022
Ellen Kurek
This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.
This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.
This study finds that US...
06/09/2022
Journal of Clinical Pathways
Conference Coverage
Bevacizumab-awwb Safe, Effective Among Patients With Metastatic Colorectal Cancer
06/04/2022
Robert Fee
Study examines real-world effectiveness and safety of Bevacizumab-awwb, the first FDA-approved biosimilar to Avastin, among patients with metastatic colorectal cancer.
Study examines real-world effectiveness and safety of Bevacizumab-awwb, the first FDA-approved biosimilar to Avastin, among patients with metastatic colorectal cancer.
Study examines real-world...
06/04/2022
Journal of Clinical Pathways
John Strickler, MD
Videos
Real-World Treatment Patterns Among Patients With HER2-Amplified Metastatic Colorectal Cancer
03/17/2022
John Strickler, MD, discusses real-world treatment patterns in patients with HER2 amplified metastatic colorectal cancer in the United States—analyzing how treatment patterns changed before 2018 and after 2018.
John Strickler, MD, discusses real-world treatment patterns in patients with HER2 amplified metastatic colorectal cancer in the United States—analyzing how treatment patterns changed before 2018 and after 2018.
John Strickler, MD, discusses...
03/17/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Doublet Therapy for Colorectal Cancer
04/13/2021
04/13/2021
Journal of Clinical Pathways
HRQoL Low Among Young Adult Colorectal Cancer Survivors
Videos
HRQoL Low Among Young Adult Colorectal Cancer Survivors
02/04/2021
Kimberly Miller, PhD, MPH, discusses results from a study exploring HRQoL in colorectal cancer survivors who were diagnosed before age 50.
Kimberly Miller, PhD, MPH, discusses results from a study exploring HRQoL in colorectal cancer survivors who were diagnosed before age 50.
Kimberly Miller, PhD, MPH,...
02/04/2021
Journal of Clinical Pathways
NCCN Guideline Adherence Improves Survival Outcomes in Anal Cancer
ENGAGING EXPERTS
NCCN Guideline Adherence Improves Survival Outcomes in Anal Cancer
02/03/2021
02/03/2021
Journal of Clinical Pathways
Conference Coverage
Tumor Mutation Burden Unlikely Biomarker for Checkpoint Inhibitor Response in CRC
02/03/2021
02/03/2021
Journal of Clinical Pathways

Expert Insights

Jeanne Tie, MBChB, MD, Peter MacCallum Cancer Centre
Videos
Circulating Tumor DNA-Guided vs Standard Management of Locally Advanced Rectal Cancer
01/20/2024
Jeanne Tie, MBChB, MD
Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.
Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.
Professor Jeanne Tie, MBChB,...
01/20/2024
Oncology
Kristin Savill, PhD
Videos
Evaluating Real-World Utilization of ctDNA Testing in the Management of Patients With Colorectal Cancer
06/30/2022
Kristin Savill, PhD, discusses her survey-based study that evaluated the utilization of circulating tumor DNA testing in the management of colorectal cancer among practicing community oncologists in the US.
Kristin Savill, PhD, discusses her survey-based study that evaluated the utilization of circulating tumor DNA testing in the management of colorectal cancer among practicing community oncologists in the US.
Kristin Savill, PhD, discusses...
06/30/2022
Journal of Clinical Pathways
John Strickler, MD
Videos
Real-World Treatment Patterns Among Patients With HER2-Amplified Metastatic Colorectal Cancer
03/17/2022
John Strickler, MD, discusses real-world treatment patterns in patients with HER2 amplified metastatic colorectal cancer in the United States—analyzing how treatment patterns changed before 2018 and after 2018.
John Strickler, MD, discusses real-world treatment patterns in patients with HER2 amplified metastatic colorectal cancer in the United States—analyzing how treatment patterns changed before 2018 and after 2018.
John Strickler, MD, discusses...
03/17/2022
Journal of Clinical Pathways
HRQoL Low Among Young Adult Colorectal Cancer Survivors
Videos
HRQoL Low Among Young Adult Colorectal Cancer Survivors
02/04/2021
Kimberly Miller, PhD, MPH, discusses results from a study exploring HRQoL in colorectal cancer survivors who were diagnosed before age 50.
Kimberly Miller, PhD, MPH, discusses results from a study exploring HRQoL in colorectal cancer survivors who were diagnosed before age 50.
Kimberly Miller, PhD, MPH,...
02/04/2021
Journal of Clinical Pathways
NCCN Guideline Adherence Improves Survival Outcomes in Anal Cancer
ENGAGING EXPERTS
NCCN Guideline Adherence Improves Survival Outcomes in Anal Cancer
02/03/2021
02/03/2021
Journal of Clinical Pathways
Videos
Why Pathways Matter: Editorial Advisory Board Testimonials
04/24/2025
Lalan Wilfong, MD
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal...
04/24/2025
Journal of Clinical Pathways
Videos
Confronting Intersectional Stigmas Across the Cancer Care Continuum
04/24/2025
Gretchen McNally, PhD, MPH, discusses how intersectional stigmas—rooted in social biases around race, gender, socioeconomic status, and other identities—negatively affect cancer care across the continuum, influencing treatment access,...
Gretchen McNally, PhD, MPH, discusses how intersectional stigmas—rooted in social biases around race, gender, socioeconomic status, and other identities—negatively affect cancer care across the continuum, influencing treatment access,...
Gretchen McNally, PhD, MPH,...
04/24/2025
Journal of Clinical Pathways
Oncology Innovations
Videos
Strengthening Pathway-Driven Care Through Payer Collaboration
04/23/2025
Gordon Kuntz; Lalan Wilfong, MD
In this episode of Oncology Innovations, Gordon Kuntz and Dr Lalan Wilfong discusses the evolving role of payers and value-based care intermediaries in oncology, emphasizing the importance of whole-person support, coordinated care, and...
In this episode of Oncology Innovations, Gordon Kuntz and Dr Lalan Wilfong discusses the evolving role of payers and value-based care intermediaries in oncology, emphasizing the importance of whole-person support, coordinated care, and...
In this episode of Oncology...
04/23/2025
Journal of Clinical Pathways
Steven Monda, MD
Videos
Evaluating the Performance of Biomarkers from Metastatic vs Primary Sites in Clear Cell Renal Cell Carcinoma
04/23/2025
Steven Monda, MD
Steven Monda, MD, shares his research on how the origin of tumor biopsies can impact biomarker performance and treatment strategies in metastatic clear cell renal cell carcinoma.
Steven Monda, MD, shares his research on how the origin of tumor biopsies can impact biomarker performance and treatment strategies in metastatic clear cell renal cell carcinoma.
Steven Monda, MD, shares his...
04/23/2025
Journal of Clinical Pathways
Hafron Headshot
Videos
Developing a National Pathway Framework for Prostate Cancer: Insights from Solaris Health
04/17/2025
Jason Hafron, MD
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how...
04/17/2025
Journal of Clinical Pathways
Adam Brufsky, MD
Interview
The Overall Cost-Effectiveness of Adjuvant Ribociclib in ER+ Early Breast Cancer
04/15/2025
Adam Brufsky, MD, PhD
Adam Brufsky, MD, PhD, discusses how adjuvant ribociclib may offer long-term value in early estrogen-receptor-positive (ER+) breast cancer by reducing costly recurrences, despite its upfront expense.
Adam Brufsky, MD, PhD, discusses how adjuvant ribociclib may offer long-term value in early estrogen-receptor-positive (ER+) breast cancer by reducing costly recurrences, despite its upfront expense.
Adam Brufsky, MD, PhD, discusses...
04/15/2025
Journal of Clinical Pathways
Figlin
Videos
Durable Responses With Belzutifan Plus Cabozantinib in Advanced RCC: Updated Findings From LITESPARK-003
04/15/2025
Robert A. Figlin, MD
In this interview, Dr Robert Figlin discusses the promising clinical activity of belzutifan combined with cabozantinib in advanced clear cell renal cell carcinoma, highlighting its potential role in future treatment pathways, practical...
In this interview, Dr Robert Figlin discusses the promising clinical activity of belzutifan combined with cabozantinib in advanced clear cell renal cell carcinoma, highlighting its potential role in future treatment pathways, practical...
In this interview, Dr Robert...
04/15/2025
Journal of Clinical Pathways
Speicher headshot
Videos
Building Smarter Pathways: How AI Can Support Precision Oncology Within a Regulatory Framework
04/11/2025
Dr Stephen Speicher highlights how evolving AI regulations, clinician collaboration, and transparent, human-centered frameworks are critical to safely integrating AI into oncology care pathways and enhancing decision-making at the point of...
Dr Stephen Speicher highlights how evolving AI regulations, clinician collaboration, and transparent, human-centered frameworks are critical to safely integrating AI into oncology care pathways and enhancing decision-making at the point of...
Dr Stephen Speicher highlights...
04/11/2025
Journal of Clinical Pathways
Sahana Somasegar
Interview
Rethinking Immunotherapy: A Case for Personalization in Advanced Endometrial Cancer
04/11/2025
A guest researcher shares a compelling case study that challenges conventional assumptions about immunotherapy in endometrial cancer, revealing how personalized treatment and multidisciplinary care enabled long-term disease control despite...
A guest researcher shares a compelling case study that challenges conventional assumptions about immunotherapy in endometrial cancer, revealing how personalized treatment and multidisciplinary care enabled long-term disease control despite...
A guest researcher shares a...
04/11/2025
Journal of Clinical Pathways
Videos
EV-302 Follow-Up Reinforces Shift in Frontline Urothelial Cancer Pathways
04/10/2025
Thomas Powles, MBBS, MD
In this interview, Dr Tom Powles discusses how updated results from the EV-302 trial confirm that enfortumab vedotin plus pembrolizumab significantly improves survival and response rates compared to standard chemotherapy in first-line...
In this interview, Dr Tom Powles discusses how updated results from the EV-302 trial confirm that enfortumab vedotin plus pembrolizumab significantly improves survival and response rates compared to standard chemotherapy in first-line...
In this interview, Dr Tom Powles...
04/10/2025
Journal of Clinical Pathways

Newsfeed

Jeanne Tie, MBChB, MD, Peter MacCallum Cancer Centre
Videos
Circulating Tumor DNA-Guided vs Standard Management of Locally Advanced Rectal Cancer
01/20/2024
Jeanne Tie, MBChB, MD
Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.
Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.
Professor Jeanne Tie, MBChB,...
01/20/2024
Oncology
Conference Coverage
Significance of ctDNA Clearance Following Adjuvant Chemotherapy Among Patients with Radically Resected Colorectal Cancer
01/20/2024
Allison Casey
According to updated results from a substudy of the observational GALAXY study, detection of MRD via ctDNA and ctDNA dynamics in response to adjuvant chemotherapy for colorectal cancer were found to be highly prognostic of patient outcomes in...
According to updated results from a substudy of the observational GALAXY study, detection of MRD via ctDNA and ctDNA dynamics in response to adjuvant chemotherapy for colorectal cancer were found to be highly prognostic of patient outcomes in...
According to updated results...
01/20/2024
Oncology
Conference Coverage
Role of ctDNA to Guide Adjuvant Chemotherapy Use for Patients With Colon Cancer
01/20/2024
Allison Casey
In the phase 2/3 COBRA study no improvement in ctDNA clearance was observed after 6 months of chemotherapy among patients with ctDNA detected following resection of stage IIA colon cancer.
In the phase 2/3 COBRA study no improvement in ctDNA clearance was observed after 6 months of chemotherapy among patients with ctDNA detected following resection of stage IIA colon cancer.
In the phase 2/3 COBRA study no...
01/20/2024
Oncology
News
Bevacizumab-bvzr Biosimilar Used Most Frequently for Metastatic Colorectal Cancer in US Oncology Practice, According to Retrospective Cohort Study
06/09/2022
Ellen Kurek
This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.
This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.
This study finds that US...
06/09/2022
Journal of Clinical Pathways
Conference Coverage
Bevacizumab-awwb Safe, Effective Among Patients With Metastatic Colorectal Cancer
06/04/2022
Robert Fee
Study examines real-world effectiveness and safety of Bevacizumab-awwb, the first FDA-approved biosimilar to Avastin, among patients with metastatic colorectal cancer.
Study examines real-world effectiveness and safety of Bevacizumab-awwb, the first FDA-approved biosimilar to Avastin, among patients with metastatic colorectal cancer.
Study examines real-world...
06/04/2022
Journal of Clinical Pathways
Conference Coverage
Tumor Mutation Burden Unlikely Biomarker for Checkpoint Inhibitor Response in CRC
02/03/2021
02/03/2021
Journal of Clinical Pathways
News
EHR-Based Model Accurately Identifies High-Risk Patients for Gastric Cancer
04/24/2025
Lisa Kuhns, PhD, MD
An electronic health record (EHR)-based logistic regression model demonstrated strong performance in identifying individuals at high risk for noncardia gastric cancer (NCGC), offering a potential tool to guide targeted screening in the US,...
An electronic health record (EHR)-based logistic regression model demonstrated strong performance in identifying individuals at high risk for noncardia gastric cancer (NCGC), offering a potential tool to guide targeted screening in the US,...
An electronic health record...
04/24/2025
Journal of Clinical Pathways
News
Myelofibrosis Symptom Assessment Tool Demonstrates Strong Validity and Reliability in Trials
04/15/2025
Lisa Kuhns, PhD, MD
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom Assessment Form Total Symptom Score version 4.0 (MFSAF TSS v4.0) reliably captures the symptom experience of patients with myelofibrosis (MF) and effectively differentiates changes over time, supporting its role as a...
The Myelofibrosis Symptom...
04/15/2025
Journal of Clinical Pathways
News
Study Links Breast Cancer Screening Rates to Social Determinants and Access to Mammography Services
04/11/2025
Hannah Musick
A nationwide study found that breast cancer screening rates are strongly influenced by social determinants and local access to mammography, with higher rates linked to education, facility proximity, and racial demographics.
A nationwide study found that breast cancer screening rates are strongly influenced by social determinants and local access to mammography, with higher rates linked to education, facility proximity, and racial demographics.
A nationwide study found that...
04/11/2025
Journal of Clinical Pathways
News
New Risk Model Enhances Prognostic Precision in Mantle Cell Lymphoma
04/10/2025
Danielle Sposato
A large retrospective study published in Scientific Reports involving 979 patients from 9 cancer centers has introduced a powerful new prognostic tool for mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma.
A large retrospective study published in Scientific Reports involving 979 patients from 9 cancer centers has introduced a powerful new prognostic tool for mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma.
A large retrospective study...
04/10/2025
Journal of Clinical Pathways
News
Health Care Burden Associated With Anemia in Ruxolitinib-Treated Myelofibrosis
04/08/2025
Juliet Gallagher
A retrospective analysis using the IQVIA PharMetrics Plus database highlights the clinical and economic burden associated with anemia in patients with myelofibrosis (MF) initiating ruxolitinib.
A retrospective analysis using the IQVIA PharMetrics Plus database highlights the clinical and economic burden associated with anemia in patients with myelofibrosis (MF) initiating ruxolitinib.
A retrospective analysis using...
04/08/2025
Journal of Clinical Pathways
News
Survival in Mantle Cell Lymphoma Improves With Shifts in Treatment Patterns
04/07/2025
Hannah Musick
A study of older MCL patients found significant survival gains linked to increased first-line use of rituximab-bendamustine (BR) and Bruton tyrosine kinase inhibitors (BTKis), but more modest improvements after second-line therapy.
A study of older MCL patients found significant survival gains linked to increased first-line use of rituximab-bendamustine (BR) and Bruton tyrosine kinase inhibitors (BTKis), but more modest improvements after second-line therapy.
A study of older MCL patients...
04/07/2025
Journal of Clinical Pathways
News
Predicting HER2 Expression in Gastric Cancer With a Deep Learning Model
04/07/2025
Juliet Gallagher
A recent study published in Advanced Science has introduced a deep learning model called HER2Net, which predicts HER2 status in gastric cancer (GC) using hematoxylin-eosin (H&E)–stained pathology slides.
A recent study published in Advanced Science has introduced a deep learning model called HER2Net, which predicts HER2 status in gastric cancer (GC) using hematoxylin-eosin (H&E)–stained pathology slides.
A recent study published in...
04/07/2025
Journal of Clinical Pathways
News
Financial Strain Persists for Patients With Cancer Despite Support Referrals
04/04/2025
Grace Taylor, MS, MA
Despite targeted support, patients with cancer face ongoing and emerging financial toxicity and health-related social risks, underscoring the need for more sustainable interventions.
Despite targeted support, patients with cancer face ongoing and emerging financial toxicity and health-related social risks, underscoring the need for more sustainable interventions.
Despite targeted support,...
04/04/2025
Journal of Clinical Pathways
Conference Coverage
Delayed EGFR Testing in Early-Stage NSCLC Linked to Increased Health Care Utilization and Cost Burden
04/01/2025
Juliet Gallagher
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is essential for guiding targeted treatment in patients with early-stage non-small cell lung cancer (eNSCLC), particularly those with EGFR mutations. Findings presented at the 2025 National Comprehensive Cancer...
Timely molecular testing is...
04/01/2025
Journal of Clinical Pathways
Conference Coverage
Study Explores Early Palliative Care Referral Patterns and Outcomes in SCLC
04/01/2025
Juliet Gallagher
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference, researchers presented findings from a retrospective study evaluating timing of palliative care referral and associated outcomes among patients with small cell lung...
At the 2025 National...
04/01/2025
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Cost-Effectiveness of Doublet Therapy for Colorectal Cancer
04/13/2021
04/13/2021
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways
JCP March/April 2025

Current Issue

April 2025
Volume 11
Issue 2
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use